Abstract 558P
Background
In Asian populations, there is a lack of substantial real-world data for brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor for patients with NSCLC. The aim of this study was to analyze real-world brigatinib treatment outcomes and dosing patterns in patients with ALK+ NSCLC who had received prior crizotinib in South Korea.
Methods
This retrospective, non-interventional cohort study used Health Insurance and Review Assessment claims data. The study included patients (>20 years old) who initiated brigatinib from 19 April 2019 to 31 March 2021 and who received crizotinib before brigatinib. We assessed patients' characteristics, treatment discontinuation, dose reduction, overall survival (OS) and adherence. Time to treatment discontinuation (TTD), time to dose reduction and OS were analyzed using Kaplan-Meier estimates. Patients whose proportion of days covered (PDC) was ≥0.8 were defined as treatment adherent.
Results
A total of 174 crizotinib-refractory patients (56.9% male; 27.1% brain metastasis history) with ALK+ NSCLC were included in the analysis (median [range] follow-up: 18 [0–34] months); the median treatment duration of prior crizotinib was 17 months. For brigatinib as second-line treatment, the median TTD was 25 months (95% CI:15.2–NE). 1- and 2-year treatment continuation rates were 63.2% and 51.5%, respectively. Median OS was not reached during the study period. The 2-year OS rate was 68.7%. 88.5% of patients reached full-dose brigatinib (180 mg/day) during treatment duration. The probability of continuing brigatinib at full dose (180 mg/day) or at peak dose (<180 mg/day) was 79.7% and 75.6% at 1 and 2 years, respectively. Overall, 93.1% of patients were adherent to brigatinib during treatment. The median PDC of brigatinib treatment was 0.98.
Conclusions
This is the first nationwide, real-world study of brigatinib treatment in a large cohort of crizotinib-refractory ALK+ NSCLC patients in South Korea. In this study, brigatinib demonstrated a longer treatment duration than in published clinical trials, as well as a favorable 2-year OS rate and high adherence. Second-line brigatinib treatment is of benefit in a real-world setting in South Korea.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Takeda.
Funding
Takeda.
Disclosure
J.H. Nam, S.H. Kwon: Financial Interests, Personal and Institutional, Research Grant: Takeda. B. Kim, S. Ha: Financial Interests, Personal, Full or part-time Employment: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract